Safety of meloxicam in patients with aspirin/non-steroidal anti-inflammatory drug-induced urticaria and angioedema

Journal of Dermatology

Volumn 37, Issue 11, 2010, Pages 973-979

  Gö Ksel, Ö Zlem ^a   Aydin, Ö Maür ^a   Misirligil, Zeynep ^a   Demirel, Yavuz S ^a   Bavbek, Sevim ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

angioedema; aspirin intolerance; drug allergy; meloxicam; non steroidal anti inflammatory drug tolerance; urticaria

Indexed keywords

ACETYLSALICYLIC ACID; MELOXICAM; NABUMETONE; NIMES; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ANGIONEUROTIC EDEMA; ARTICLE; ASTHMA; ATOPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG DOSE INCREASE; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERANCE; DYSPNEA; ERYTHEMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NOSE CONGESTION; PRURITUS; RHINORRHEA; SIDE EFFECT; SINGLE BLIND PROCEDURE; SNEEZING; URTICARIA; WHEEZING;

ADMINISTRATION, ORAL; ADULT; ANGIOEDEMA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CYCLOOXYGENASE 2 INHIBITORS; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; MALE; MIDDLE AGED; SINGLE-BLIND METHOD; SKIN TESTS; THIAZINES; THIAZOLES; TREATMENT OUTCOME; URTICARIA;

EID: 78349264599     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2010.00948.x     Document Type: Article

References (31)

1. Szczeklik A, Niżankowska-Mogilnicka E, Sanak M,. Hypersensitivity to aspirin and non-sterodal antiinflammatory drugs. In:, Adkinson NF, eds. Middleton's Allergy. Principles and Practice, 7th edn. Philadelphia: Elsevier Inc., 2009; 1227-1243.
2. Viola M, Quaratino D, Gaeta F, Rumi G, Caruso C, Romano A,. Cross-reactive reactions to nonsteroidal anti-inflammatory drugs. Curr Pharm Des 2008; 14: 2826-2832.
3. Chen Y-F, Jobanputra P, Barton P, et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2008; 12: 1-196.
4. Bavbek S, Celik G, Ozer F, Mungan D, Misiriligil Z,. Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of Nimesulide, Meloxicam, and Rofecoxib. J Asthma 2004; 41: 67-75.
5. Bavbek S, Celik G, Pasaoglu G, Misirligil Z,. Rofecoxib, as a safe alternative for acetyl salicylic acid/nonsteroideal anti-inflammatory drug-intolerant patients. J Investig Allergol Clin Immunol 2006; 16: 57-62.
6. Celik G, Pasaoglu G, Bavbek S, et al. Tolerability of selective cyclooxygenase inhibitor, celecoxib, in patients with analgesic intolerance. J Asthma 2005; 42: 127-131. (Pubitemid 40570818)
7. Szczeklik A, Nizankowska E, Bochenec G, Nargraba K, Mejza F, Swierczynska M,. Safety of specific COX-2 inhibitor in aspirin-induced asthma. Clin Exp Allergy 2001; 31: 219-225.
8. Senna G, Biló MB, Antonicelli L, et al. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients. Allerg Immunol (Paris) 2004; 36: 215-218.
9. Prieto A, De Barrio M, Martin E, et al. Tolerability to nabumetone and meloxicam in patients with nonstreoidal anti-inflammatory drug intolerance. J Allergy Clin Immunol 2007; 119: 960-964.
10. Quaratino D, Ramono A, Di Fonso M, et al. Tolerability of meloxicam in patients with histories of adverse reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2000; 84: 613-617.
11. Kosnik M, Music E, Matjaz F, Suskovic S,. Relative safety to meloxicam in NSAID-intolerant patients. Allergy 1998; 53: 1231-1233.
12. Bavbek S, Dursun AB, Dursun E, Eryilmaz A, Misirligil Z,. Safety of meloxicam in Aspirin-intolerant patients with asthma and/or nasal polyps: a challenge-proved study. Int Arch Allergy Immunol 2007; 142: 64-69.
13. Senna G, Passalacqua G, Dama A, et al. Nimesulide and meloxicam are safe alternative drugs for patients intolerant to nonstreoidal anti-inflammatory drugs. Allergol Immunol (Paris) 2003; 35: 393-396.
14. Karakaya G, Fuat K,. Safety of nimesulide, meloxicam and rofecoxib as alternative analgesics. Allergol Immunopathol 2000; 28: 319-321.
15. Sánchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F,. The multipl faces of nonsteroidal anti-inflammatory drug hypersensitivity. J Investig Allergol Clin Immunol 2004; 14: 329-334.
16. Stevenson DD, Sánchez-Borges M, Szczeklik A,. Classification of allergic and pseudoallergic reactions to drugs that inhibit cycloxygenase enzymes. Ann Allergy Asthma Immunol 2001; 87: 177-180.
17. Sánchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F,. NSAID-Induced Urticaria and Angioedema. A reappraisal of its clinical management. Am J Clin Dermatol 2002; 3: 599-607.
18. Nettis E, Di Paola R, Ferrannini A, Tursi A,. Meloxicam in hypersensitivity to NSAID. Allergy 2001; 56: 803-804.
19. Domingo MV, Marchuet MJC, Culla MTD, Joanpere RS, Guanado EM,. Meloxicam tolerance in hypersensitivity to nonsteroidal anti-inflammatory drugs. J Investig Allergol Clin Immunol 2006; 16: 364-366.
20. Sánchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F, Ramon Pérez C,. Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions. Ann Allergy Asthma Immunol 2001; 87: 201-204.
21. Sánchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F,. Cutaneous Hypersensitivity reactions to inhibitors of Cyclooxygenase-2. Results from 307 oral provocation tests and review of the literature. Allergy Clin Immunol Int-J World Org 2007; 19: 44-49.
22. Inomata N, Osuna H, Yamaguchi J, et al. Safety of selective cyclooxygenase-2 inhibitors and a basic non-steroidal anti-inflammatory drug (NSAID) in Japanese patients with NSAID induced urticaria and/or angioedema: comparison of meloxicam, etodolac and tiaramide. J Dermatol 2007; 34: 172-177.
23. çelik G, Mungan D, Bavbek S, Sin B, Demirel YS, Misirligil Z,. The prevalence of allergic diseases and atopy in Ankara, Turkey: a two-step population-based epidemiological study. J Asthma 1999; 36: 281-290.
24. Quiralte J, San Pedro BS, Florido JF,. Safety of selective cycloxygenase-2 inhibitor rofecoxib in patients with NSAID-induced cutaneous reactions. Ann Allergy Asthma Immunol 2002; 89: 63-66.
25. Namazy JA, Simon RA,. Sensitivity to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2002; 89: 542-550.
26. Simon RA, Stevenson DD,. Cross-reactivity of cyclooxygenase 2 inhibitors in patients with a history of cutaneous reactions to cyclooxygenase 1 inhibitors. Ann Allergy Asthma Immunol 2005; 95: 8-11.
27. Mastalerz L, Setkowicz M, Sanak M, Szczeklik A,. Hypersensitivity to aspirin: common eicosanoid alterations in urticaria and asthma. J Allergy Clin Immunol 2004; 113: 771-775.
28. Mastalerz L, Setkowicz M, Szczeklik A,. Mechanism of chronic urticaria exacerbation by aspirin. Curr Allergy Asthma Rep 2005; 5: 227-283.
29. Ispano M, Fontana A, Scibilia J, Ortolani C,. Oral challenge with alternative nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol in patients intolerant to these agents. Drug 1993; 46 (Suppl 1): 253-256.
30. Bavbek S, Erkekol FO, Dursun B, Misirligil Z,. Meloxicam-associated anaphylactic reaction. J Investig Allergol Clin Immunol 2006; 16: 317-320.
31. Bavbek S,. Use of safe alternatives in ASA/NSAID-intolerant patients. In:, Charles LM, eds. New Research on Aspirin and Health. New York: Nova Science Publishers, Inc, 2007; Chapter IX, 213-230.